World Orphan Drug Congress USA 2025
22-24 April 2025
Boston Convention & Exhibition Center
Book a meetingSciensus is proud to sponsor the upcoming World Orphan Drug Congress USA 2025.
The World Orphan Drug Congress is a key event for industry leaders, bringing together pharmaceutical companies, regulators, and patient advocacy groups to advance access to rare disease treatments.
Join us and discover your European end-to-end commercialisation partner for your rare and orphan medicines.
Are you navigating the complexities of launching orphan drugs in Europe?
Don’t miss our two must-attend speaking sessions at the World Orphan Drug Congress USA 2025, where we’ll share actionable insights to help U.S. biotechs succeed in the European market.
Breaking into Europe: Partnerships That Propel U.S. Biotechs to Orphan Drug Success
Time: 1:00pm – 2:00pm
Expanding into Europe comes with unique challenges—diverse regulations, cultural nuances, and high risks. Discover how strategic partnerships can streamline market entry, mitigate risks, and enhance access efficiency.
Key takeaways:
- The key challenges U.S. biotechs face in Europe
- Strategies to navigate market complexities
- How collaboration drives successful drug launches
Sciensus speakers: Mathieu Loiseau , Andrew Cummins , Alastair Macdonald , Ray Huml
Guest speakers: Ms. Kathy Senecal, Grant Castor
Tuesday April 22nd
Breaking into Europe: Partnerships That Propel U.S. Biotechs to Orphan Drug Success
Time: 1:00pm – 2:00pm
Expanding into Europe comes with unique challenges—diverse regulations, cultural nuances, and high risks. Discover how strategic partnerships can streamline market entry, mitigate risks, and enhance access efficiency.
Key takeaways:
- The key challenges U.S. biotechs face in Europe
- Strategies to navigate market complexities
- How collaboration drives successful drug launches
Sciensus speakers: Mathieu Loiseau , Andrew Cummins , Alastair Macdonald , Ray Huml
Guest speakers: Ms. Kathy Senecal, Grant Castor
Wednesday April 23rd
Driving Reimbursement Success in Europe with Real-World Evidence – A Case Study
Time: 2:50pm – 3:10pm
Reimbursement is the gateway to patient access – learn how Real-World Evidence (RWE) strengthens the case for approval, ensuring equitable access across Europe.
Key takeaways:
- How RWE supports cost-effectiveness and clinical value
- Bridging data gaps for small patient populations
- Navigating Europe’s complex reimbursement landscape
Sciensus speakers: Mathieu Loiseau , Andrew Cummins
Join us for an exclusive fringe event on Tuesday, 22nd of April
On the evening of day 1, we’ll be hosting an invitation-only networking event. This will be an intimate gathering for a fireside chat exploring the intersection of art and science in the rare disease space with voices from both the scientific and creative worlds.
Our facilitator, Dr. Ray Huml, will be joined Patty Welton, CEO of Beyond the Diagnosis, an organisation known for painting powerful portraits of children living with life-altering conditions, including rare diseases; Kim LeBlanc, Director, Undiagnosed Diseases Network (UDN), Harvard Medical School; and Michele Herndon, Program Director, Undiagnosed Diseases Network Foundation (UDNF).
The evening will create space for thought-provoking dialogue, reflection, and connection. We’d love to see you there.
Meet us at the event
Join us and discover your European end-to-end commercialisation partner for your rare and orphan medicines.
Learn more about our bespoke rare and orphan disease medicine solution
Expanded access program
Our partners benefit from our regulatory, marketing and commercial strategy expertise, ensuring a faster and easier route to market.
Supply chain management
Sciensus makes the typically complex process of rare disease medicine supply and distribution simple
Real-world data
Partner with Sciensus to develop a Digital+ PSP that drives better outcomes for your patients and demonstrates real-world treatment value.
Patient support programs
Through our patient-facing applications, we generate key insights that enable us to drive the right interventions at the right time, further enhancing the effectiveness of our PSPs.
About Sciensus
Sciensus is a proven life sciences solutions partner with more than 30 years’ experience in navigating and unlocking the complex European healthcare ecosystem to maximise patient reach. We help accelerate the development journey, bringing medicines into the market and directly to patients to improve health outcomes. Through cutting-edge patient engagement programmes, offering an exclusive combination of skilled in-person care and digital support, we help patients make the most of their treatment and generate real-world evidence that can be used to improve treatment pathways.